Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

7
Mid-Year REIT Market Update

2018-07-05 seekingalpha
Between the four REIT team members, we met with over 50 REIT management teams at the June REITWeek conference.
KRC.PRG BPY KRC.PRH DCT KRC BXP TCO KRG UDR LSI TRNO EQR MAC JCAP.PRB AVB REG.PRG REG.PRF VNO EQIX TCO.PRK TCO.PRJ FR FRT JBGS RVI JCAP SPG QTS WPG PEI REG DLR.PRH DLR.PRG DLR.PRJ DLR.PRI SKT CXP EXR CONE COR ESS GGP EGP DDR MNR ROIC UE RPAI PLD SPG.PRJ KRLP OFC IRT BXP.PRB REXR DLR LPT DLR.PRC WRI DLR.PRF ESRT

17
Office REITs: Jobs, Jobs, Jobs

2018-06-05 seekingalpha
Despite a record 92 consecutive months of job growth, office REITs have yet to fully recover from the previous recession. The sector has been a perennial underperformer since 2007.
DEI EQC EQC.PRD EQCO PGRE BXP.PRB BXP ESRT

244
You Say 'Vornado', I Say 'Vornado'

2018-05-31 seekingalpha
Maybe it’s a southern thing, because when I’m in Manhattan, my fellow analysts pronounce it Vor-nah-to.
WFCNP MS.PRE WFC.PRL UE.WI MS.PRF BXP WFC.PRJ MS.PRG MS.PRA STWD.WI BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO UBS WFC.PRN UBS.PRDCL MS WFC.PRY WFC.PRX WFC.PRW AB WFC.PRV WFC WFC.WS C UE MS.PRI JBGS MS.PRK BXP.PRB MSFT STWD SLG ULSGF ESRT

1
ESRT / Empire State Realty Trust, Inc. FORM 8-K (Current Report)

2018-05-22 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ESRT

0
ESRT / Empire State Realty Trust, Inc. / COHEN & STEERS INC - null (Passive Investment)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.9) Empire State Realty Trust, Inc. ----------------------------------- (Name of Issuer) Common Stock ----------------- (Title of Class of Securities) 292104106 ---------
ESRT

1
ESRT / Empire State Realty Trust, Inc. / COHEN & STEERS INC - null (Passive Investment)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.9) Empire State Realty Trust, Inc. ----------------------------------- (Name of Issuer) Common Stock ----------------- (Title of Class of Securities) 292104106 ---------
ESRT

0
25
New Strong Sell Stocks for April 27th

2018-04-27 zacks
Apogee Enterprises, Inc. (APOG - Free Report) is a designer of glass products and services. The Zacks Consensus Estimate for its current year earnings has been revised 12% downward over the last 30 days.
GIS FBC B ESRT APOG

0
Empire State Realty Trust, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-04-26 seekingalpha
The following slide deck was published by Empire State Realty Trust, Inc. in conjunction with their 2018 Q1 earnings call.
ESRT

28
Empire State Realty Trust's (ESRT) CEO Tony Malkin on Q1 2018 Results - Earnings Call Transcript

2018-04-26 seekingalpha
Empire State Realty Trust, Inc. (NYSE:ESRT) Q1 2018 Earnings Conference Call April 26, 2018 8:30 AM ET
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV ESRT

1
ESRT / Empire State Realty Trust, Inc. FORM 8-K (Current Report)

2018-04-25 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ESRT

0
ESRT / Empire State Realty Trust, Inc. FORM 8-K (Current Report)

2018-04-25 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ESRT

10
New Strong Sell Stocks for April 13th

2018-04-13 zacks
Clearwater Paper Corporation (CLW - Free Report) is a seller of private label tissue and bleached paperboard products. The Zacks Consensus Estimate for its current year earnings has been revised 8.1% downward over the last 30 days.
HMST GSM GNC HBIO FWRD CLW ESRT PTIE

0
ESRT / Empire State Realty Trust, Inc. DEF 14A

2018-04-05 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A
ESRT

46
Virtu Financial, Empire State Realty Trust, Dillard's, Burlington Stores and Macy's highlighted as Zacks Bull and Bear of the Day

2018-04-05 zacks
Chicago, IL – April 5, 2018 – Zacks Equity Research highlights Virtu Financial (VIRT - Free Report) as the Bull of the Day, Empire State Realty Trust (ESRT - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Dillard's (DDS - Free Report) , Burlington Stores (BURL - Free Report) and Macy’s (M - Free Report) .
DDS LINDW BURL STLD LHCG LCII M CLAC ZBRA LSTR CVGW VIRT PATK CLACW CLACU SAIC FG LIND ESRT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 292104106